Loiasis

Summary

Loiasis (MONDO:0016566) is a disease and 11 clinical trials. Top therapeutic interventions include diethylcarbamazine, ivermectin, and albendazole. A subtype of filariasis — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
• Clinical trials: 11

Clinical features

Epidemiology

Prevalence records

2 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Point prevalence	<1 / 1 000 000		Europe	Validated
Point prevalence	>1 / 1000		Specific population	Not yet validated

Identifiers

Disease identifiers

Field	Value
Canonical name	loiasis
Mondo ID	MONDO:0016566
EFO	EFO:1000729
MeSH	D008118
Orphanet	2404
DOID	DOID:13523
ICD-10-CM	B74.3
ICD-11	709184369
NCIT	C34784
SNOMED CT	44250009
UMLS	C0023968
MedGen	6132
GARD	0003283
MedDRA	10024797
Is cancer (heuristic)	no

Also known as: African eye worm · Loa loa filariasis

Disease family

This is a subtype of filariasis. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › helminthiasis › filariasis › loiasis

Related subtypes (6): filarial elephantiasis, mansonelliasis, setariasis, dirofilariasis, dracunculiasis, onchocerciasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Diethylcarbamazine, Reslizumab.

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	4
Not specified	3
PHASE4	2
PHASE2/PHASE3	1
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01593722	PHASE4	COMPLETED	Post-treatment Effects of Ivermectin (IVM) or Diethylcarbamazine (DEC) in Loiasis
NCT05085665	PHASE4	COMPLETED	Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events
NCT06252961	PHASE2/PHASE3	RECRUITING	A 3- to 5-day Clinical Trial of Levamisole in Loiasis Infected Subjects
NCT06613997	PHASE3	NOT_YET_RECRUITING	21-day Double-blind Trial of Albendazole in Adults With Loa Loa Microfilaremia
NCT01111305	PHASE2	COMPLETED	Reslizumab to Prevent Post-treatment Eosinophilia in Loiasis
NCT02644525	PHASE2	TERMINATED	Efficacy and Microfilaricidal Kinetics of Imatinib for the Treatment of Loa Loa
NCT04049630	PHASE2	COMPLETED	Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients
NCT04049851	PHASE2	COMPLETED	Clinical Trial Evaluating the Safety and Efficacy of Moxidectin 2 mg Ivermectin-controlled in Loa Loa Microfilaremic Patients
NCT06350851	Not specified	RECRUITING	Development of a New Rapid Diagnostic Test to Support Onchocerciasis Elimination
NCT04035174	Not specified	WITHDRAWN	Evaluation of the Diagnosis Performances of DEC LTS-2 Skin Patch for Onchocerciasis in Central Africa
NCT04258670	Not specified	UNKNOWN	Spontaneous Antigenemia in Loiasis

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
DIETHYLCARBAMAZINE	4	2
IVERMECTIN	4	2
ALBENDAZOLE	4	1
LEVAMISOLE	4	1
RESLIZUMAB	4	1
DEXAMISOLE	2	1
CHEMBL263291	0	2
CHEMBL4082099	0	2
CHEMBL4788951	0	2